As Health Problems Mount Patients Welcome New Treatments

By Patricia Miller

In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Healthcare is changing, as more and more diseases pose a growing concern for society and the companies trying to cure them.

There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer, and diabetes, pose a growing burden to health care systems and humanity alike. As health-aware patients seek a diagnosis from a younger age and populations live longer, cases are mounting. Here we discuss growing health problems with reference to Takeda Pharmaceutical (NYSE: TAK), Abbott Laboratories (NYSE: ABT), Bristol-Myers Squibb (NYSE: BMY), Novo Nordisk (NYSE: NVO), and Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL).

Takeda is making progress in treating cancer and gastrointestinal conditions, Bristol-Myers Squibb is making strides in oncology medications, Abbott labs is tackling diabetes, and Novo Nordisk is developing life-altering diabetes and weight loss drugs.

Meanwhile, heart failure comes in various forms, and some, such as acute myocarditis and diastolic heart failure, currently have no recognized standard of care.

Heart failure has remained the leading cause of death globally for the last 20 years, further exacerbated by mounting diabetes, obesity, and high blood pressure cases. This devastating condition comes in several forms, but ultimately leads to diminished quality of life and death.

Every year, over 550,000 new cases are diagnosed in the U.S. That's why Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is working vigorously to develop treatments to help people live more comfortably with this destructive disease.

Cardiol Therapeutics is focused on researching and developing an anti-inflammatory and anti-fibrotic therapy to treat cardiovascular diseases (CVD). Its lead product candidate, CardiolRx™, is a pharmaceutically produced oral formulation being clinically designed for use in cardiovascular medicine.

The company currently has one multi-national clinical trial ongoing, with another expected to commence shortly. Furthermore, it just announced its third FDA IND authorization for its flagship formulation CardiolRx™ in cardiovascular disease.

Altogether, the company is looking to treat acute myocarditis, recurrent pericarditis, and diastolic heart disease.


Cardiol's latest IND authorization is for a multicenter Phase II open-label pilot study of CardiolRx™ for recurrent pericarditis. This study will run parallel with the company's multi-national Phase II acute myocarditis trial, which is expected to commence imminently.

The company will evaluate whether this intervention could be a therapeutic option for those who are intolerant to current medical treatment or who require long-term administration of corticosteroids to control their disease.

Dr. Allan L. Klein, Director Center of Pericardial Diseases and Professor of Medicine, Heart and Vascular Institute, Cleveland Clinic, will serve as study Chair and provide leadership throughout the trial.

Cardiol's study is expected to enroll 25 patients at major clinical centers specializing in pericarditis in the United States. The study protocol has been designed in collaboration with well-established thought leaders in pericardial disease.

Pericarditis refers to inflammation of the pericardium – the membrane, or sac, surrounding the heart. Symptoms include debilitating chest pain, shortness of breath, and fatigue, which result in physical limitations, reduced quality of life, emergency department visits, and hospitalizations.

Causes of pericarditis can include infection (e.g., tuberculosis), systemic disorders such as autoimmune and inflammatory diseases, cancer, and post-cardiac injury syndromes.

Recurrent pericarditis is the reappearance of symptoms after a symptom-free period of at least 4–6 weeks following an episode of acute pericarditis. These recurrences appear in 15% to 30% of acute cases and usually within 18 months.

Up to 50% of patients with a recurrent episode of pericarditis experience more recurrences.

Cardiol believes there is a significant opportunity to develop a new oral, well-tolerated, and safe therapy for treating recurrent pericarditis to prevent multiple recurrences in the first place, particularly for colchicine-resistant, intolerant, refractory, and contraindicated patients, and steroid-dependent patients.

With the world facing intensifying healthcare challenges, doctors welcome breakthroughs in treating the most prevalent of diseases.

Takeda Pharmaceutical (NYSE: TAK) recently launched two new products, lung cancer med Exkivity and anti-cytomegalovirus drug Livtencity. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). The company also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines.

Abbott Laboratories (NYSE: ABT) announced late-breaking clinical data that demonstrates its FreeStyle Libre® 3 system has an overall mean absolute relative difference (MARD) of 7.9%,1 making it the first and only 14-day continuous glucose monitoring (CGM) system to achieve a sub-8% overall MARD. The results were presented at the American Diabetes Association® (ADA) 82nd Scientific Sessions, June 3-7, 2022, in New Orleans.

Bristol-Myers Squibb Co (NYSE: BMY) is acquiring Turning Point Therapeutics, a leading precision oncology company. The acquisition brings Repotrectinib, a potential best-in-class, next-generation ros1/ntrk inhibitor with differentiated duration of response for patients with ros1-positive first-line non-small cell lung cancer. This drug is expected to launch in 2023. BMY’s all-cash tender offer will acquire all outstanding shares of turning point therapeutics for $76 per share.

Novo Nordisk A/S (NYSE: NVO) announced headline results from the main phases of its ONWARDS 1 (52 weeks) and ONWARDS 6 (26 weeks) phase 3a trials with once-weekly insulin icodec. In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile. This has the potential to become the ideal insulin for people with type 2 diabetes initiating insulin treatment.

Explore more on these topics:



This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of One Hundred and Eighty Thousand Dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR+ and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter